A major focus of virology is the development of antiviral drugs, a class of medication used to treat viral infections. Antiviral drug development is challenging as compounds must selectively inhibit viral replication without damaging the host. Viruses evolve rapidly, continuously presenting new targets for antiviral drugs and making previous drugs less effective. With the recent outbreaks of SARS-CoV-2 (COVID-19), Ebola, Zika, influenza, and other viral infections, efforts to develop broad-spectrum antivirals, which are effective against a wide range of viral infections, have increased to treat emerging and re-emerging viral infections.
Axion BioSystems' Maestro Z, ZHT, Pro, and Edge systems offers impedance-based cell analysis for real-time, continuous, label-free monitoring of cytopathic effects (CPEs). Continuous data reveals the kinetics of in vitro viral infections for more complete dataset without the time- and cost-intensive process of repeating multiple endpoint assays.
Antiviral drug assays to track cytopathic effects
-
Screen antiviral drugs for SARS-CoV-2 (COVID-19)>
-
Remdesivir prevents cell death from SARS-CoV-2>
-
Assay Steps>
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2. While early symptoms may present as relatively mild, they can develop into acute respiratory distress syndrome (ARDS) as the virus damages and disrupts healthy lung tissue. Axion BioSystems' Maestro Z, ZHT, Pro, and Edge systems makes it quick and easy to evaluate virus-induced cytopathic effects (CPE).
Vero E6 cells were seeded into the CytoView-Z 96-plate and impedance was continuously monitored on the Maestro Z system. After 24 hours, test compounds and SARS-CoV-2 were added. Antiviral drugs resulted in a dose dependent decrease in cell death in the presence of virus with the exception of Drugs 3 and 4 at their highest concentrations, likely due to their own toxicity. Infected and uninfected wells show low and high impedance values, respectively.
